吉利德捐赠240万瓶特鲁瓦达,以遏制美国艾滋病毒感染

2019-05-14 不详 MedSci原创

美国的艾滋病病毒感染率持续走高,为了遏制病毒的蔓延,政府官员正在向制药商寻求的帮助。现在,吉利德(Gilead Sciences)已向美国疾病控制和预防中心承诺捐赠240万瓶艾滋病预防性特鲁瓦达Truvada,用于减少新的感染。

美国的艾滋病病毒感染率持续走高,为了遏制病毒的蔓延,政府官员正在向制药商寻求帮助。目前,吉利德(Gilead Sciences)已向美国疾病控制和预防中心承诺捐赠240万瓶艾滋病预防性特鲁瓦达Truvada,用于减少新的感染

Truvada是一种被批准用于预防HIV感染的抗逆转录病毒药物,主要成分为恩曲他滨和替诺福韦。该药物2018年在美国的销售额达26亿美元,成为仿制药商的重要目标。

吉利德首席病人官Gregg Alton表示:"我们相信今天的捐赠,再加上一些用于解决HIV流行病感染根源的措施,如种族主义、对妇女的暴力、耻辱、同性恋恐惧症和变性恐惧症,可以在结束美国的艾滋病流行方面发挥重要作用。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798075, encodeId=70ec1e98075cf, content=<a href='/topic/show?id=5ae9680603f' target=_blank style='color:#2F92EE;'>#特鲁瓦达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68060, encryptionId=5ae9680603f, topicName=特鲁瓦达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Jun 06 09:18:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756951, encodeId=30251e56951be, content=<a href='/topic/show?id=db7856538ee' target=_blank style='color:#2F92EE;'>#捐赠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56538, encryptionId=db7856538ee, topicName=捐赠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce7f37274706, createdName=ms1692212821629096, createdTime=Fri Oct 18 14:18:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948855, encodeId=d46b1948855b1, content=<a href='/topic/show?id=8b7b86814c6' target=_blank style='color:#2F92EE;'>#艾滋病毒感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86814, encryptionId=8b7b86814c6, topicName=艾滋病毒感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Mar 24 15:18:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366412, encodeId=9cc63664126b, content=关注艾滋防治,舒发泰, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2531680715, createdName=1de33e15m69(暂无匿称), createdTime=Sat May 18 23:06:36 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798075, encodeId=70ec1e98075cf, content=<a href='/topic/show?id=5ae9680603f' target=_blank style='color:#2F92EE;'>#特鲁瓦达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68060, encryptionId=5ae9680603f, topicName=特鲁瓦达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Jun 06 09:18:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756951, encodeId=30251e56951be, content=<a href='/topic/show?id=db7856538ee' target=_blank style='color:#2F92EE;'>#捐赠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56538, encryptionId=db7856538ee, topicName=捐赠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce7f37274706, createdName=ms1692212821629096, createdTime=Fri Oct 18 14:18:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948855, encodeId=d46b1948855b1, content=<a href='/topic/show?id=8b7b86814c6' target=_blank style='color:#2F92EE;'>#艾滋病毒感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86814, encryptionId=8b7b86814c6, topicName=艾滋病毒感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Mar 24 15:18:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366412, encodeId=9cc63664126b, content=关注艾滋防治,舒发泰, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2531680715, createdName=1de33e15m69(暂无匿称), createdTime=Sat May 18 23:06:36 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798075, encodeId=70ec1e98075cf, content=<a href='/topic/show?id=5ae9680603f' target=_blank style='color:#2F92EE;'>#特鲁瓦达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68060, encryptionId=5ae9680603f, topicName=特鲁瓦达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Jun 06 09:18:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756951, encodeId=30251e56951be, content=<a href='/topic/show?id=db7856538ee' target=_blank style='color:#2F92EE;'>#捐赠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56538, encryptionId=db7856538ee, topicName=捐赠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce7f37274706, createdName=ms1692212821629096, createdTime=Fri Oct 18 14:18:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948855, encodeId=d46b1948855b1, content=<a href='/topic/show?id=8b7b86814c6' target=_blank style='color:#2F92EE;'>#艾滋病毒感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86814, encryptionId=8b7b86814c6, topicName=艾滋病毒感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Mar 24 15:18:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366412, encodeId=9cc63664126b, content=关注艾滋防治,舒发泰, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2531680715, createdName=1de33e15m69(暂无匿称), createdTime=Sat May 18 23:06:36 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798075, encodeId=70ec1e98075cf, content=<a href='/topic/show?id=5ae9680603f' target=_blank style='color:#2F92EE;'>#特鲁瓦达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68060, encryptionId=5ae9680603f, topicName=特鲁瓦达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Jun 06 09:18:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756951, encodeId=30251e56951be, content=<a href='/topic/show?id=db7856538ee' target=_blank style='color:#2F92EE;'>#捐赠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56538, encryptionId=db7856538ee, topicName=捐赠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce7f37274706, createdName=ms1692212821629096, createdTime=Fri Oct 18 14:18:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948855, encodeId=d46b1948855b1, content=<a href='/topic/show?id=8b7b86814c6' target=_blank style='color:#2F92EE;'>#艾滋病毒感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86814, encryptionId=8b7b86814c6, topicName=艾滋病毒感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Mar 24 15:18:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366412, encodeId=9cc63664126b, content=关注艾滋防治,舒发泰, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2531680715, createdName=1de33e15m69(暂无匿称), createdTime=Sat May 18 23:06:36 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
    2019-05-18 1de33e15m69(暂无匿称)

    关注艾滋防治,舒发泰

    0

相关资讯

吉利德“新官”上任三把火:为Kite求贤、加码并购以及组织调整

吉利德科学去年任命Daniel O'Day为董事会主席兼首席执行官,该任命自2019年3月1日起正式生效。吉利德此举是鉴于Daniel O’Day在癌症领域的相关经验,新官上任三把火在世界通用,Daniel O’Day上任后也在着手进行一些策略调整。

吉利德科学公司修订索华迪®(索磷布韦片)说明书

索磷布韦片(Sofosbuvir),商品名为索华迪®(SOVALDI®),是吉利德(Gilead)科学公司研发的产品,至今共修订该药品说明书8次。吉利德科学公司根据《联邦食品药品和化妆品法案》第505(b)条规定提交补充新药申请(sNDA),提出修订索磷布韦片(400 mg)说明书,并于2017年11月9日发布新版说明书,修订补充申请-12(SUPPL-12)说明书的内容。1 索华迪®简介索磷布韦

吉利德HIV药物Truvada(特鲁瓦达)获英国NICE支持用于HIV暴露前预防治疗(PrEP)

美国生物技术巨头吉利德(Gilead)艾滋病管线近日在英国监管方面传来喜讯,英国国家卫生与临床优化研究所(NICE)已发布了一份有关HIV复方药Truvada用于感染高风险成人群体暴露前预防性治疗(PrEP)的证据总结。根据已获得的证据,Truvada在降低高危未感染成人群体中获得性HIV感染风险方面具有显著的临床疗效。此外,这份证据总结也表明,提供PrEP可能会增加其他健康服务的获取,例如艾

重磅:吉利德乙肝药物Vemlidy获欧盟批准进入欧洲市场

据悉,欧洲委员会已经授权吉利德的药物Vemlidy进入欧洲市场,这标志着欧盟近十年来首个乙肝病毒(HBV)疗法获批。 经过对主席11月批准建议的确认,欧盟点头授权吉利德乙肝药物进入欧洲市场,可在欧盟28个成员国以及挪威和冰岛进行成年人及青少年HBV感染的治疗。 早在2016年年末,该药物就已经获得美国FDA批准用于治疗成年人HBV感染及控制肝病,同时也获得日本卫生、劳动和福利部门的批准。

罗氏、吉利德、默沙东……跨国公司高管大变动

又到了年底换帅高峰期时,谁将接替吉利德科学 CEO John Milligan的悬念终于被揭晓。

吉利德遭起诉 涉嫌隐瞒使用未批准的中国产药物

近日,原本胜诉的吉利德被告知诉讼已被再次重启。原因是,吉利德将未经批准的中国产恩曲他滨用于艾滋病毒药物活性成分,并谎称该成分来自一家获得批准的、价格更贵的韩国制造商。